EP1417199A1 - Nouvelles modifications du sel de trometamol de l'acide r-thioctique, ainsi que procedes pour leur production - Google Patents

Nouvelles modifications du sel de trometamol de l'acide r-thioctique, ainsi que procedes pour leur production

Info

Publication number
EP1417199A1
EP1417199A1 EP20020743253 EP02743253A EP1417199A1 EP 1417199 A1 EP1417199 A1 EP 1417199A1 EP 20020743253 EP20020743253 EP 20020743253 EP 02743253 A EP02743253 A EP 02743253A EP 1417199 A1 EP1417199 A1 EP 1417199A1
Authority
EP
European Patent Office
Prior art keywords
modification
preparation
mixtures
addition
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20020743253
Other languages
German (de)
English (en)
Inventor
Gunter Laban
Wolfgang Sauer
Annegret Jannasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Publication of EP1417199A1 publication Critical patent/EP1417199A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the invention relates to new modifications of the trometamol seed of R-thioctic acid of the formula I,
  • This compound is, for example, anti-inflammatory and cytoprotective (EP 427247) and is used for the treatment of diabetes mellitus and insulin resistance (DE 4,343,593) as well as for glucose metabolism disorders of the CNS (DE 4,343,592) and as an appetite suppressant (DE 19.818.563) used and can therefore be used in pharmaceutical preparations (EP 702953).
  • the requirements for an active ingredient with regard to the physicochemical properties relevant for galenical processability and bioavailability are determined both by the type and the manufacturing technology of the respective pharmaceutical preparation.
  • the physicochemical properties significantly influence the galenic processability and bioavailability.
  • the invention is therefore based on the object of providing compound I in various modifications and mixtures thereof in accordance with the pharmaceutical requirements.
  • the two modifications have different physicochemical properties.
  • the characteristic X-ray powder diffractograms are used.
  • the modifications also differ in their DSC curves (Differential Scanning Calorimetry), by the typical crystal shapes, the different solubilities or dissolution rates and the different flowability.
  • Solvents such as lower alcohols, octanol and acetone and their
  • R-thioctic acid polymerizes easily and tends to react in this way, especially in polar media.
  • modifications A and B of the compound I and their mixtures of any composition can be obtained either by salt formation of R-thioctic acid with trometamol in suitable polar solvents such as, for example, lower alcohols as well as by modification conversion under special reaction conditions.
  • nucleophilic compounds such as e.g. Sodium sulfite or 6,8-dimercaptooctanoic acid, in the salt formation with R-thioctic acid as the main product produced according to synthesis route a, the modification B.
  • modifications can also be made by modification conversion, whereby a complete or partial conversion from A to B and from B to A can take place.
  • a melt of modification A preferably about 10 to 40 min at about 115-130 ° C, in particular 15 to 25 min at about 115-120 ° C, and crystallization by Cooling.
  • modifications A and B and their mixtures can be processed in a conventional manner with suitable carriers and / or auxiliaries to give pharmaceutical preparations.
  • suitable carriers and / or auxiliaries to give pharmaceutical preparations.
  • Preferred forms of use are tablets and capsules.
  • Diacel filter aid
  • Example 6 25.8 g (0.125 mol) of R-thioctic acid (prepared by method b) were dissolved in 375 ml of ethanol (anhydrous). Subsequently, 15.13 g (0.125 mol) of trometamol were introduced and the mixture was heated with stirring at 50-55 ° C. until dissolved.
  • Diacel 1 g was stirred at 53-55 ° C for 20 min, suction filtered and the solution slowly cooled.
  • Example 24 10 g of I, modification A, were dissolved in 30 ml of ethanol (96%) at 55 ° C. The mixture was then concentrated on a rotary evaporator to a maximum bath temperature of 100 ° C., finally under vacuum. The oil crystallized on cooling: mixture (approx. 1: 1) of modifications A and B, yield quantitative.
  • R-thioctic acid prepared by process b
  • 100 g of R-thioctic acid were dissolved in a mixture consisting of 760 ml of cyclohexane and 40 ml of water-saturated ethyl acetate (water content: 3.2%) at 40-42 ° C.
  • the product was filtered with suction, slowly cooled to -5 ° C., stirred at this temperature for 1 h, suction filtered, washed with cyclohexane and dried at 30 ° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

L'invention concerne de nouvelles modifications du sel de trométamol de l'acide R-thioctique de formule (I). L'invention concerne également des procédés pour la production de ces modifications, des compositions pharmaceutiques les contenant et leur application médicale.
EP20020743253 2001-07-31 2002-07-02 Nouvelles modifications du sel de trometamol de l'acide r-thioctique, ainsi que procedes pour leur production Withdrawn EP1417199A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10137381A DE10137381A1 (de) 2001-07-31 2001-07-31 Neue Modifikationen des Trometamolsalzes der R-Thioctsäure sowie Verfahren zu ihrer Herstellung
DE10137381 2001-07-31
PCT/EP2002/007310 WO2003011852A1 (fr) 2001-07-31 2002-07-02 Nouvelles modifications du sel de trometamol de l'acide r-thioctique, ainsi que procedes pour leur production

Publications (1)

Publication Number Publication Date
EP1417199A1 true EP1417199A1 (fr) 2004-05-12

Family

ID=7693786

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20020743253 Withdrawn EP1417199A1 (fr) 2001-07-31 2002-07-02 Nouvelles modifications du sel de trometamol de l'acide r-thioctique, ainsi que procedes pour leur production

Country Status (9)

Country Link
US (3) US6844449B2 (fr)
EP (1) EP1417199A1 (fr)
JP (1) JP2005506969A (fr)
KR (1) KR100913684B1 (fr)
CN (2) CN100410248C (fr)
CA (1) CA2451979C (fr)
DE (1) DE10137381A1 (fr)
HK (1) HK1098743A1 (fr)
WO (1) WO2003011852A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10201464B4 (de) * 2002-01-16 2005-06-16 Viatris Gmbh & Co. Kg Verfahren zur Herstellung reiner Thioctsäure
US20070299093A1 (en) * 2005-01-27 2007-12-27 Alma Mater Studiorum-Universitá Di Bologna Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation
CA2595994A1 (fr) * 2005-01-27 2006-08-03 Alma Mater Studiorum - Universita' Di Bologna Composes organiques convenant pour le traitement de la maladie d'alzheimer, utilisation et methode de fabrication
KR20110103987A (ko) * 2008-12-01 2011-09-21 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
CN105622571A (zh) * 2016-03-08 2016-06-01 苏州富士莱医药股份有限公司 一种r-硫辛酸氨基丁三醇盐的制备方法
CN113200959A (zh) * 2020-12-16 2021-08-03 南京海融制药有限公司 一种硫辛酸氨丁三醇盐晶型及其制备方法
CN113197845A (zh) * 2020-12-16 2021-08-03 南京海融制药有限公司 一种硫辛酸氨丁三醇注射液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES323195A1 (es) * 1966-02-17 1966-12-01 Ferrer Labor Procedimiento de obtenciën de compuestos de acciën antiacidëtica
PT95826B (pt) 1989-11-09 1997-11-28 Asta Medica Ag Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
DE4037440A1 (de) 1990-11-24 1992-05-27 Basf Ag Verfahren zur herstellung von (6s)-6,8-dihydroxyoctansaeureestern
DE4137773A1 (de) 1991-11-16 1993-05-19 Degussa Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure
DE4235912C2 (de) * 1992-10-23 2002-12-05 Viatris Gmbh Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4343592C2 (de) 1993-12-21 1998-04-16 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE19533881A1 (de) 1995-09-13 1997-03-20 Dresden Arzneimittel Herstellung und Verwendung der reinen Enantiomere der 8-Chlor-6-sulfonyloxy-octansäuren und ihrer Alkylester und der reinen Enantiomere der 6,8-Dichlor-octansäure und ihrer Alkylester
DE19533882A1 (de) 1995-09-13 1997-03-20 Dresden Arzneimittel Herstellung und Verwendung der reinen Enantiomere der 8-Halogen-6-hydroxyoctansäuren, ihrer Alkylester und ihrer Salze mit reinen Enantiomeren des alpha-Methylbenzylamins
DE19709069C2 (de) 1997-03-06 2000-04-06 Asta Medica Ag Enantiomerenreine 3-Hydroxyoctandisäurediester, Verfahren zur Herstellung derselben durch asymmetrische katalytische Hydrierung sowie Verfahren zur Herstellung von R-(+)- und S-(-)-alpha-Liponsäure
DE19818563C2 (de) 1998-04-25 2003-04-17 Sueddeutsche Kalkstickstoff Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung
DE19834608A1 (de) * 1998-07-31 2000-02-03 Basf Ag Kristallmodifikation der Liponsäure
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
IT1319194B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido tiottico racemo.
IT1319195B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido r(+)alfa-lipoico.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03011852A1 *

Also Published As

Publication number Publication date
DE10137381A1 (de) 2003-02-13
JP2005506969A (ja) 2005-03-10
CN100410248C (zh) 2008-08-13
US6844449B2 (en) 2005-01-18
CN1537109A (zh) 2004-10-13
US20040225007A1 (en) 2004-11-11
KR20040043171A (ko) 2004-05-22
US7030251B2 (en) 2006-04-18
KR100913684B1 (ko) 2009-08-24
CN1309718C (zh) 2007-04-11
CN1869033A (zh) 2006-11-29
WO2003011852A1 (fr) 2003-02-13
HK1098743A1 (en) 2007-07-27
US20030050332A1 (en) 2003-03-13
CA2451979A1 (fr) 2003-02-13
US20050004208A1 (en) 2005-01-06
CA2451979C (fr) 2011-09-13

Similar Documents

Publication Publication Date Title
DE3025856A1 (de) Amidderivate, verfahren zu deren herstellung und arzneimittel
EP0096297B1 (fr) Procédé de préparation de dérivés de 1-sulfo-2-oxoazétidine
WO1993004035A1 (fr) Nouveaux derives 3,5-di-tert.butyl-4-hydroxyphenyles, leur procede de fabrication et medicaments les renfermant
DE60105113T2 (de) Verfahren zur Herstellung von einem Kristallepoxid
DE60311516T2 (de) Perindopril
EP1417199A1 (fr) Nouvelles modifications du sel de trometamol de l'acide r-thioctique, ainsi que procedes pour leur production
EP0028765A1 (fr) Dérivés de l'alkylurée pour le traitement des maladies du métabolisme des graisses; procédé pour leur préparation, leur application dans des médicaments pour le traitement des altérations du métabolisme des graisses, médicaments les contenant, procédé pour leur préparation, ainsi que quelques dérivés de l'alkylurée
DE2112026B2 (de) 3-Phenyl-H2-[pyrroUdinyl-(l)] äthylamino)-3,4dihydroisochinolin, seiner Herstellung und die es enthaltenden medizinischen Zusammensetzungen
DE2628558A1 (de) Verfahren zur herstellung von lofepraminhydrochlorid
EP0622366B1 (fr) Quinolyl-dihydropyridines condensées, procédé pour leur préparation et leur utilisation comme médicament pour le traitement de maladies circulatoires du coeur
DE60116514T2 (de) Amlodipinhemimaleat
DE2903615A1 (de) Guajakacylester von mercaptopropionsaeurederivaten, verfahren zu ihrer herstellung und ihre therapeutische verwendung
WO1979000426A1 (fr) Diamine cyclique n, n'-disubstituee et procede pour sa preparation
DE3223877C2 (fr)
DE60011739T2 (de) Kristallines oder kristallisiertes Säureadditionssalz von Losartan und Verfahren zur Reinigung von Losartan
DE2717001A1 (de) Arzneimittel mit antithrombotischer wirkung
WO2001040229A2 (fr) Procede de preparation d'hydrochlorure d'epinastine dans le cadre de la modification cristalline a point de fusion eleve
CH649998A5 (de) Ergolinderivate, ein verfahren zu ihrer herstellung und heilmittel, enthaltend diese ergolinderivate als wirkstoff.
DE2927452A1 (de) Neue derivate des daunorubicins, ihre herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen
DE2709109A1 (de) Verfahren zur herstellung von 1-tert.butylamino-3-(2,5-dichlorphenoxy)-2-propanol einschliesslich seiner enantiomere sowie von saeureadditionssalzen desselben
DE2435222C2 (de) Verfahren zur Herstellung von N-(2-Diethylamino)-ethyl-2-methoxy-5-methylsulfonylbenzamid
AT389310B (de) Cyclohexandion-derivat und verfahren zu seiner herstellung
DE69915274T2 (de) Verfahren zur herstellung von methyl(2s)-2-[(3r)-3-(n-[tert-butyloxycarbonyl -amino -2-oxopyrrolidin-1-yl]propionate
DE2521159C2 (de) Verfahren zur Herstellung von N-(4-Fluorphenyl)-2,3-dichlormaleinsäureimid
AT221531B (de) Verfahren zur Herstellung von neuen Barbitursäure-Verbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1066006

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VIATRIS GMBH & CO. KG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDA PHARMA GMBH & CO. KG

17Q First examination report despatched

Effective date: 20070612

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEGUSSA GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EVONIK DEGUSSA GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EVONIK DEGUSSA GMBH

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1066006

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120922